EBO Raises Seed Round Led by Olea Venture Partners to Scale AI Patient Engagement Platform

EBO Secures Seed Funding Led by Olea Venture Partners

EBO, a Malta-founded AI company building patient engagement and workflow automation software for healthcare organisations, has raised a Seed round led by Olea Venture Partners. The funding date is recorded as October 2, 2026. The round type is Seed; the specific funding amount was not disclosed in the available data.

What EBO Does

EBO develops software that combines conversational and agentic AI with behavioural science to automate high-volume patient interactions. Its platform is designed to handle tasks such as appointment management, self-assessments, and care-pathway communications.

A distinguishing characteristic of EBO's approach is its positioning: the platform runs as infrastructure inside regulated clinical workflows rather than as a standalone tool. This means it is intended to integrate directly into the systems and processes that healthcare organisations already use, rather than operating alongside them as a separate application.

Commercial Footprint

EBO has commercial operations in four markets:

• United Kingdom
• Italy
• Greece
• Malta

The company reports live deployments across UK NHS Trusts and hospitals, indicating that its software is already in active use within the UK's public healthcare system.

Why This Matters for the Healthcare AI Market

Healthcare organisations face persistent pressure to manage high volumes of patient interactions efficiently while maintaining compliance with clinical and regulatory requirements. EBO's focus on automating routine but essential communications — appointment scheduling, patient self-assessments, and care-pathway messaging — targets a category of work that is repetitive, time-sensitive, and often resource-intensive for clinical and administrative teams.

By embedding behavioural science into its AI-driven interactions, EBO aims to improve how patients engage with these communications, which can influence outcomes such as appointment attendance and completion of assessments. The combination of conversational AI and agentic capabilities suggests the platform is designed not only to respond to patient queries but also to take actions within workflows.

The Investor

Olea Venture Partners led the Seed round. No additional investors were listed in the available data.

What's Next

With Seed funding in place, EBO is positioned to build on its existing deployments across UK NHS Trusts and hospitals and its commercial presence in the UK, Italy, Greece, and Malta. The company operates in a segment where integration into regulated clinical workflows is a key differentiator, and its existing live deployments provide a foundation for further expansion.

For those tracking healthcare AI and patient engagement infrastructure, EBO represents a company to watch as it scales its platform across European healthcare markets.